(All fields required)
Please enter a valid email.
Please enter your name.
Paul E. Steele, MD Medical Director, Clinical Laboratory
Medical Director, Clinical Laboratory
Associate Professor, UC Department of Pediatrics
Paul E. Steele, MD, is medical director of the clinical laboratory at Cincinnati Children's Hospital Medical Center, arriving in 1999. He came to Children's Hospital Medical Center of Cincinnati from University Hospital of Cincinnati, where he was a member of the laboratory medicine staff for 11 years.
Dr. Steele's background includes general laboratory directorship, as he was Medical Director of University Hospital's Immediate Response Laboratory for over two years before coming to Cincinnati Children's.
Dr. Steele has also served as medical director of Diagnostic Immunology since arriving at University Hospital. In this position, he was involved in humoral immunology, including infectious disease serology, autoimmune testing, protein characterization, and allergy testing; he was also involved in flow cytometry, including transplantation, stem cell and HIV monitoring, as well as evaluation and monitoring of hematopoietic neoplasms.
Dr. Steele has also been involved in molecular pathology. At University Hospital, he put in place a molecular diagnostics laboratory which provided molecular genetic detection of lymphoid clonality as well as chromosomal translocation in chronic myelocytic leukemia. At Children's Hospital Medical Center of Cincinnati, he has become a participant in overseeing the molecular genetic testing for infectious disease.
Dr. Steele's research interests include the evaluation of human endogenous retroviral sequences and their role in human pathology. This work is an outgrowth of studies he began as a postdoctoral fellow at the National Institutes of Health.
Specifically, Dr. Steele has created antisera to a biosynthetic fusion protein containing a portion of a human endogenous retroviral envelope gene that encodes a putative immunosuppressive protein. This antisera detects a human protein which is the subject of Dr. Steele's study.
MD: University of Missouri, Kansas City, 1978.
Residency: Anatomic Pathology, Massachusetts General Hospital, Boston 1978-81; Clinical Pathology, Barnes Hospital, St. Louis, MO, 1984-86.
Fellowships: Basic science fellowship, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, 1981-84.
Certification: Anatomic and Clinical Pathology, 1987.
Prasad Devarajan, MD Director, Division of Nephrology and Hypertension
Director, Division of Nephrology and Hypertension
Medical Director, Stone Center
Director, Nephrology and Hypertension Clinical Laboratory
Louise M. Williams Endowed Chair
Professor, UC Department of Pediatrics
Clinical specialties: Acute kidney injury, nephrotic syndrome, kidney stones
Visit the Devarajan Lab.
Czech KA, Bennett M, Devarajan P. Distinct metalloproteinase excretion patterns in focal segmental glomerulosclerosis. Pediatr Nephrol. 2011 Jul 1.
Askenazi DJ, Koralkar R, Levitan EB, Goldstein SL, Devarajan P, Khandrika S, Mehta RL, Ambalavanan N. Baseline Values of Candidate Urine Acute Kidney Injury (AKI) Biomarkers Vary by Gestational Age in Premature Infants. Pediatr Res. 2011 Jun 3. Abraham BP, Frazier EA, Morrow WR, Blaszak RT, Devarajan P, Mitsnefes M, Bryant JC, Sachdeva R. Cystatin C and neutrophil gelatinase-associated lipocalin as markers of renal function in pediatric heart transplant recipients. Pediatr Transplant. 2011 Apr 25. Sundaram N, Bennett M, Wilhelm J, Kim MO, Atweh G, Devarajan P, Malik P. Biomarkers for early detection of sickle nephropathy. Am J Hematol. 2011 Jul;86(7):559-66. Devarajan P, Krawczeski C. In reply to 'antifibrinolytic use during cardiac and hepatic surgery makes tubular proteinuria-based early biomarkers poor tools to diagnose perioperative acute kidney injury'. Am J Kidney Dis. 2011 Jun;57(6):960-1. Piyaphanee N, Ma Q, Kremen O, Czech K, Greis K, Mitsnefes M, Devarajan P, Bennett MR. Discovery and initial validation of α 1-B glycoprotein fragmentation as a differential urinary biomarker in pediatric steroid-resistant nephrotic syndrome. Proteomics Clin Appl. 2011 Jun;5(5-6):334-42.
Li S, Krawczeski CD, Zappitelli M, Devarajan P, Thiessen-Philbrook H, Coca SG, Kim RW, Parikh CR; for the TRIBE-AKI Consortium. Incidence, risk factors, and outcomes of acute kidney injury after pediatric cardiac surgery: A prospective multicenter study. Crit Care Med. 2011 Jun;39(6):1493-1499. Krawczeski CD, Woo JG, Wang Y, Bennett MR, Ma Q, Devarajan P. Neutrophil gelatinase-associated lipocalin concentrations predict development of acute kidney injury in neonates and children after cardiopulmonary bypass. J Pediatr. 2011 Jun;158(6):1009-1015.e1.
Basu RK, Devarajan P, Wong H, Wheeler DS. An update and review of acute kidney injury in pediatrics. Pediatr Crit Care Med. 2011 May;12(3):339-47.
Devarajan P. Biomarkers for the early detection of acute kidney injury. Curr Opin Pediatr. 2011 Apr;23(2):194-200.
Lawrence M. Dolan, MD Director, Division of Endocrinology
Director, Division of Endocrinology
Director, Endocrinology Clinical Laboratory
Epidemiology and genetics of obesity; insulin resistance; abnormal carbohydrate metabolism; diabetes and their relationships to the development and progression of cardiovascular disease
Lawrence M. Dolan, MD, is board-certified in pediatrics and pediatric endocrinology. He has been on the faculty of Cincinnati Children's Hospital Medical Center in the Department of Pediatrics for the University of Cincinnati College of Medicine since 1983.
Dr. Dolan is a professor of pediatrics in the Division of Endocrinology. His research focuses on the epidemiology and genetics of obesity, insulin resistance, abnormal carbohydrate metabolism, diabetes and their relationships to the development and progression of cardiovascular disease.
Dr. Dolan received his bachelor of science degree from the University of San Francisco. He received his doctor of medicine degree from the University of California at Los Angeles.
Dr. Dolan completed his pediatric internship and residency at the University of Minnesota. He also served as chief resident. He obtained fellowship training in pediatric endocrinology at the University of Virginia.
Shah AS, Dolan LM, Gao Z, Kimball TR, Urbina EM. Racial differences in arterial stiffness among adolescents and young adults with type 2 diabetes. Pediatr Diabetes. 2011 Jul 25. Epub ahead of print.
Dabelea D, Pihoker C, Talton JW, D'Agostino RB Jr, Fujimoto W, Klingensmith GJ, Lawrence JM, Linder B, Marcovina SM, Mayer-Davis EJ, Imperatore G, Dolan LM; SEARCH for Diabetes in Youth Study. Etiological approach to characterization of diabetes type: the SEARCH for Diabetes in Youth Study. Diabetes Care. 2011 Jul;34(7):1628-33.
Hilliard ME, Guilfoyle SM, Dolan LM, Hood KK. Prediction of adolescents' glycemic control 1 year after diabetes-specific family conflict: the mediating role of blood glucose monitoring adherence. Arch Pediatr Adolesc Med. 2011 Jul;165(7):624-9.
Urbina EM, Khoury PR, McCoy C, Daniels SR, Kimball TR, Dolan LM. Cardiac and vascular consequences of pre-hypertension in youth. J Clin Hypertens (Greenwich). 2011 May;13(5):332-42.
Hood KK, Rausch JR, Dolan LM. Depressive symptoms predict change in glycemic control in adolescents with type 1 diabetes: rates, magnitude, and moderators of change. Pediatr Diabetes. 2011 May 12. Epub ahead of print.Urbina EM, Dolan LM, McCoy CE, Khoury PR, Daniels SR, Kimball TR. Relationship between elevated arterial stiffness and increased left ventricular mass in adolescents and young adults. J Pediatr. 2011 May;158(5):715-21.
Shah AS, Khoury PR, Dolan LM, Ippisch HM, Urbina EM, Daniels SR, Kimball TR. The effects of obesity and type 2 diabetes mellitus on cardiac structure and function in adolescents and young adults. Diabetologia. 2011 Apr;54(4):722-30. Nommsen-Rivers LA, Dolan LM, Huang B. Timing of Stage II Lactogenesis Is Predicted by Antenatal Metabolic Health in a Cohort of Primiparas. Breastfeed Med. 2011 Apr 27. Epub ahead of print. Kaulfers AM, Bean JA, Inge TH, Dolan LM, Kalkwarf HJ. Bone loss in adolescents after bariatric surgery. Pediatrics. 2011 Apr;127(4):e956-61. Epub 2011 Mar 28. Dabelea D, Dolan LM, D'Agostino R Jr, Hernandez AM, McAteer JB, Hamman RF, Mayer-Davis EJ, Marcovina S, Lawrence JM, Pihoker C, Florez JC. Association testing of TCF7L2 polymorphisms with type 2 diabetes in multi-ethnic youth. Diabetologia. 2011 Mar;54(3):535-9.
Alexandra (Lisa) H. Filipovich, MD Ralph J. Stolle Chair, Clinical Immunology
Ralph J. Stolle Chair, Clinical Immunology
Director, Immune Deficiency and Histiocytosis Program
Medical Director, Diagnostic Immunology Laboratory
Primary immunodeficiencies; BMT for primary immunodeficiencies; hemophagocytic lymphocytosis; post-BMT immune reconstruction
Biology and genetics of hemophagocytic lymphohistiocytosis; investigation of hematopoietic cell transplantation for genetic immunodeficiencies; immunoreconstitution following pediatric stem cell transplantation
Jodele S, Bleesing JJ, Mehta PA, Filipovich AH, Laskin BL, Goebel J, Pinkard SL, Davies SM. Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2010 Nov 5.
Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, Mehta PA, Davies SM, Jordan MB, Bleesing JJ, Filipovich AH. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010 Dec 23;116(26):5824-31. Marsh RA, Bleesing JJ, Filipovich AH. Using flow cytometry to screen patients for X-linked lymphoproliferative disease due to SAP deficiency and XIAP deficiency. J Immunol Methods. 2010 Oct 31;362(1-2):1-9. Laskin BL, Goebel J, Davies SM, Khoury JC, Bleesing JJ, Mehta PA, Filipovich AH, Paff ZN, Lawrence JM, Yin HJ, Pinkard SL, Jodele S. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2010 Aug 9. Filipovich AH, Zhang K, Snow AL, Marsh RA. X-linked lymphoproliferative syndromes: brothers or distant cousins? Blood. 2010 Nov 4;116(18):3398-408. Marsh RA, Madden L, Kitchen BJ, Mody R, McClimon B, Jordan MB, Bleesing JJ, Zhang K, Filipovich AH. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood. 2010 Aug 19;116(7):1079-82.
Marsh RA, Satake N, Biroschak J, Jacobs T, Johnson J, Jordan MB, Bleesing JJ, Filipovich AH, Zhang K. STX11 mutations and clinical phenotypes of familial hemophagocytic lymphohistiocytosis in North America. Pediatr Blood Cancer. 2010 Jul 15;55(1):134-40.
Filipovich AH. Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology Am Soc Hematol Educ Program. 2009:127-31.
Nicolaou SA, Neumeier L, Takimoto K, Lee SM, Duncan HJ, Kant SK, Mongey AB, Filipovich AH, Conforti L. Differential calcium signaling and Kv1.3 trafficking to the immunological synapse in systemic lupus erythematosus. Cell Calcium. 2010 Jan;47(1):19-28.
Marsh RA, Villanueva J, Kim MO, Zhang K, Marmer D, Risma KA, Jordan MB, Bleesing JJ, Filipovich AH. Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T-cell populations. Clin Immunol. 2009 Jul;132(1):116-23.
Gene Therapy for SCID-X1 Using Self-Inactivating Gamma. Principal Investigator. National Institutes of Health. Sep 2010-Aug 2015. #U01 AI 087628.
Rare Diseases Clinical Consortia for the Rare Diseases. Principal Investigator. National Institutes of Health. Sep 2009-Aug 2014. #U54 AI 082973.
Hypoxia and potassium channel activity in T Lymphocytes. Principal Investigator. National Institutes of Health. Jun 2009-Jun 2014. #R01 CA 095286.
Ralph A. Gruppo, MD Director, Comprehensive Hemophilia and Thrombosis Center
Director, Comprehensive Hemophilia and Thrombosis Center
Director, Research Coagulation Laboratory
Director, Special Hemostasis & Thrombosis Laboratory
Coagulation; hemophilia; thrombosis
Gruppo RA. Treatment of hemophilia in developing countries: a journey of a thousand miles. Pediatr Blood Cancer. 2010 Mar;54(3):348-9. No abstract available
Gelfand MJ, Gruppo RA, Nasser MP. Ventilation-perfusion scintigraphy in children and adolescents is associated with a low rate of indeterminate studies. Clin Nucl Med. 2008 Sep;33(9):606-9.
Wu SW, Graham B, Gelfand MJ, Gruppo RE, Dinopolous A, Gilbert DL. Clinical and positron emission tomography findings of chorea associated with primary antiphospholipid antibody syndrome. Mov Disord. 2007 Sep 15;22(12):1813-5.
Balasa VV, Gruppo RA, Glueck CJ, Wang P, Roy DR, Wall EJ, Mehlman CT, Crawford AH. Legg-Calve-Perthes disease and thrombophilia. J Bone Joint Surg Am. 2004 Dec;86-A(12):2642-7.
Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII -- a robust meta-analytic finding. Haemophilia. 2004 Sep;10(5):449-51.
Morrison JA, Gruppo R, Glueck CJ, Stroop D, Fontaine RN, Wang P, Smith KL. Population-specific alleles: the polymorphism (K121Q) of the human glycoprotein PC-1 gene is strongly associated with race but not with insulin resistance in black and white children. Metabolism. 2004 Apr;53(4):465-8.
Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis -- a meta-analysis. Haemophilia. 2003 May;9(3):251-60. Review.
Balasa VV, Kalinyak KA, Bean JA, Stroop D, Gruppo RA. Hyperhomocysteinemia is associated with low plasma pyridoxine levels in children with sickle cell disease. J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):374-9.
McNamara JL, Lombardi JP, Ferguson R, Manning PB, Gruppo RA. Alternative methods for anticoagulation monitoring in pediatric patients with applicability to a patient with severe hemophilia A and circulating inhibitor. J Extra Corpor Technol. 2001 Dec;33(4):239-42.
Gruppo R, Degrauw A, Fogelson H, Glauser T, Balasa V, Gartside P. Protein C deficiency related to valproic acid therapy: a possible association with childhood stroke. J Pediatr. 2000 Nov;137(5):714-8.
Punam Malik, MD Director, Comprehensive Sickle Cell Program
Director, Comprehensive Sickle Cell Program
Director, Translational Trials Development and Support Laboratory
Program Leader, Molecular and Gene Therapy Program
Arumugam P, Malik P. Genetic therapy for beta-thalassemia: from the bench to the bedside. Hematology Am Soc Hematol Educ Program. 2010;2010:445-50.
Perumbeti A, Malik P. Therapy for beta-globinopathies: a brief review and determinants for successful and safe correction. Ann N Y Acad Sci. 2010 Aug;1202:36-44. Review.
Perumbeti A, Malik P. Genetic correction of sickle cell anemia and beta-thalassemia: progress and new perspective. Scientific World Journal. 2010 Apr 13;10:644-54. Review.
Sundaram N, Tailor A, Mendelsohn L, Wansapura J, Wang X, Higashimoto T, Pauciulo MW, Gottliebson W, Kalra VK, Nichols WC, Kato GJ, Malik P. High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Blood. 2010 Jul 8;116(1):109-12.
Wang D, Zhang W, Kalfa TA, Grabowski G, Davies S, Malik P, Pan D. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19958-63.
Arumugam PI, Urbinati F, Velu CS, Higashimoto T, Grimes HL, Malik P. The 3' region of the chicken hypersensitive site-4 insulator has properties similar to its core and is required for full insulator activity. PLoS One. 2009 Sep 10;4(9):e6995.
Arumugam PI, Higashimoto T, Urbinati F, Modlich U, Nestheide S, Xia P, Fox C, Corsinotti A, Baum C, Malik P. Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region. Mol Ther. 2009 Nov;17(11):1929-37.
Perumbeti A, Higashimoto T, Urbinati F, Franco R, Meiselman HJ, Witte D, Malik P. A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. Blood. 2009 Aug 6;114(6):1174-85.
Urbinati F, Arumugam P, Higashimoto T, Perumbeti A, Mitts K, Xia P, Malik P. Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3'LTR. Mol Ther. 2009 Sep;17(9):1527-36.
Williams JP, Wu J, Johansson G, Rizvi TA, Miller SC, Geiger H, Malik P, Li W, Mukouyama YS, Cancelas JA, Ratner N. Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential. Cell Stem Cell. 2008 Dec 4;3(6):658-69.
Mark M. Mitsnefes, MD, MS Director, Clinical and Translational Research Center
Director, Clinical and Translational Research Center
Nephrology with focus on chronic kidney disease and hypertension
Mark Mitsnefes, MD, MS, is an established clinical investigator with expertise in the area of understanding the development of risk factors for cardiovascular disease in children with chronic kidney disease. The long-term goal of his research is to define biologic targets for interventions to prevent and slow progression of cardiovascular disease in children with chronic kidney disease.
Dr. Misnefes has received numerous awards, including the Proctor Scolar Award (Cincinnati Children's Research Foundation), the Pediatrician Scientist Award (Children's Health Research Center, NIH), the Clinical Scientist Award (National Kidney Foundation), and has been ranked as one of the Best Doctors in America, 2007-2011.
MD: Gorky Medical Institute, Gorky, Russia, 1985.Residency: Miami Children's Hospital, Miami, Florida, 1997.Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 2000.
MS: Epidemiology and Biostatistics, University of Cincinnati, Cincinnati, Ohio, 2001.
Certifications: Educational Commission for Foreign Medical Graduates (ECFMG), 1995; Pediatrics, 1996; Pediatric Nephrology, 2001, 2008.
Mitsnefes M, Flynn J, Cohn S, Samuels J, Blydt-Hansen T, Saland J, Kimball T, Furth S, Warady B; CKiD Study Group. Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol. 2010 Jan;21(1):137-44.
Wilson AC, Mitsnefes MM. Cardiovascular disease in CKD in children: update on risk factors, risk assessment, and management. Am J Kidney Dis. 2009 Aug;54(2):345-60. Review.
Flynn JT, Mitsnefes MM, Pierce C, Cole SR, Parekh RS, Furth SL and Warady BA. Blood pressure in children with chronic kidney disease: Preliminary findings from chronic kidney disease in children cohort study. Hypertension. 2008;52(4):631-7
Weaver DJ Jr, Kimball T, Witt SA, Glascock BJ, Khoury PR, Kartal J, Mitsnefes MM. Subclinical systolic dysfunction in pediatric patients with chronic kidney disease. J Pediatr. 2008 Oct;153(4):565-9.
Weaver DJ Jr., Kimball TR, Knilans T, Mays WK, Knecht T, Gerdes YT, Witt S, Glascock BJ, Kartal J, Khoury PR, and Mitsnefes MM. Decreased maximal aerobic capacity in pediatric chronic kidney disease. J Am Soc Nephrol. 2008, 19(3):624-30.
Mitsnefes MM, Kimball TR, Kimball TR, Witt SA, Glascock BJ, Khoury PR, and Daniels SR. Abnormal carotid artery structure and function in children with successful renal transplant. Circulation. 2004; 110:97-101.
Mitsnefes MM, Kimball TR, Kartal J, Witt SA, Glascock B, Khoury PR, Daniels SR. Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: Role of calcium-phosphorus metabolism. J Am Soc Nephrol. 2005;16:2796-2803.
Mitsnefes MM, Kimball TR, Border WL, Witt SA, Glascock BJ, Khoury PR and Daniels SR. Impaired left ventricular diastolic function in children with chronic renal failure. Kidney Int. 2004;65(4):1461-1466.
Mitsnefes MM, Kimball TR, Witt SA, Glascock BJ, Khoury PR, and Daniels SR. Left ventricular mass and systolic performance in pediatric patients with chronic renal failure. Circulation. 2003;107:864-868
Mitsnefes MM, Daniels SR, Schwartz SM, Khoury P, Meyer RA, and Strife CF. Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol. 2000;14:898-902.
Adiponectin and Cardiovascular Disease in the CKiD Children. Principal Investigator. National Institutes of Health. 2007 - 2011. #R01 DK076957.
Modify Dietary Behavior in Adolescents with Elevated Blood Pressure. Co-investigator. National Institutes of Health. 2007 - 2012.
Prospective study of chronic kidney disease in children. Co-investigator, Co-chair of the Cardiovascular Committee. National Institutes of Health. 2003 - 2013. #U01 DK-03-012.
Cardiovascular disease in children with CKD. Principal Investigator. National Institutes of Health. 2011 - 2016. #K24 DK090070-01.
Joel E. Mortensen, PhD Director, Diagnostic Infectious Diseases Testing Laboratory (Microbiology and Virology)
Director, Diagnostic Infectious Diseases Testing Laboratory (Microbiology and Virology)
Dr. Mortensen's current research focus is antimicrobial susceptibility testing of fastidious pediatric pathogens.
Dr. Mortensen is a career academic clinical microbiologist in the Department of Pathology and Laboratory Medicine at Cincinnati Children's since 1991. Beyond providing consultation to the medical staff in Clinical Microbiology, his clinical interests include the application of rapid testing methods into the clinical microbiology laboratory and outpatient settings and LEAN manufacturing processes applied to Clinical Microbiology. His collaborations with faculty and fellows have resulted in more than 100 peer-reviewed publications, case studies and text chapters.
Motley WW, Melson AT, Mortensen JE. Pediatric Metarhizium anisopliae keratitis. J AAPOS. 2011 Feb 10.
Major TA, Panmanee W, Mortensen JE, Gray LD, Hoglen N, Hassett DJ. Sodium nitrite-mediated killing of the major cystic fibrosis pathogens Pseudomonas aeruginosa, Staphylococcus aureus, and Burkholderia cepacia under anaerobic planktonic and biofilm conditions. Antimicrob Agents Chemother. 2010 Nov;54(11):4671-7.
Chhabra MS, Motley WW 3rd, Mortensen JE. Eikenella corrodens as a causative agent for neonatal conjunctivitis. J AAPOS. 2008 Oct;12(5):524-5.
Huppert JS, Mortensen JE, Reed JL, Kahn JA, Rich KD, Hobbs MM. Mycoplasma genitalium detected by transcription-mediated amplification is associated with Chlamydia trachomatis in adolescent women. Sex Transm Dis. 2008 Mar;35(3):250-4.
Huppert JS, Mortensen JE, Reed JL, Kahn JA, Rich KD, Miller WC, Hobbs MM. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clin Infect Dis. 2007 Jul 15;45(2):194-8.
Huppert JS, Biro F, Lan D, Mortensen JE, Reed J, Slap GB. Urinary symptoms in adolescent females: STI or UTI? J Adolesc Health. 2007 May;40(5):418-24.
Iyer SB, Gerber MA, Pomerantz WJ, Mortensen JE, Ruddy RM. Effect of point-of-care influenza testing on management of febrile children. Acad Emerg Med. 2006 Dec;13(12):1259-68.
Huppert JS, Gerber MA, Deitch HR, Mortensen JE, Staat MA, Adams Hillard PJ. Vulvar ulcers in young females: a manifestation of aphthosis. J Pediatr Adolesc Gynecol. 2006 Jun;19(3):195-204.
Mortensen JE, Gerrety MJ, Gray LD. Surveillance of antimicrobial resistance in Neisseria meningitidis from patients in the Cincinnati Tri-State region (Ohio, Kentucky, and Indiana). J Clin Microbiol. 2006 Apr;44(4):1592-3.
Yoon SS, Coakley R, Lau GW, Lymar SV, Gaston B, Karabulut AC, Hennigan RF, Hwang SH, Buettner G, Schurr MJ, Mortensen JE, Burns JL, Speert D, Boucher RC, Hassett DJ. Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions. J Clin Invest. 2006 Feb;116(2):436-46.
Charles T. Quinn, MD, MS Director, Hematology Clinical and Translational Research
Director, Hematology Clinical and Translational Research
Director, Hemoglobinopathy Laboratory
Sickle cell disease; thalassemia; hemoglobinopathies; anemia; autoimmune hemolytic anemia; disorders of red blood cells; iron overload and iron chelation; chronic transfusion therapy; immune thrombocytopenia (ITP); neutropenia; stroke
Epidemiology, pathophysiology, treatment and prevention of brain injury (structural and cognitive) in sickle cell disease; measurement of red blood cell turnover in sickle cell disease; identification and treatment of cardiomyopathy and nephropathy in sickle cell disease; treatment and prevention of pain (VOC) in sickle cell disease; MRI methods of iron quantitation; new agents for immune thrombocytopenia (ITP)
Dr. Quinn’s main interests and expertise are in patient-oriented and translational research in sickle cell disease and thalassemia. His formal clinical and translational research training has included: (1) the NIH-K30 Curriculum in Patient-Oriented Research; (2) the Clinical Research Training Institute of the American Society of Hematology; (3) the NIH-K12/KL2 Clinical Scholars Program; and (4) a master’s degree in clinical sciences. Dr. Quinn is a member of the Editorial Board for Pediatric Blood and Cancer and the Board of Contributing Editors for The Hematologist. Dr. Quinn is on the Medical Advisory Board for the Cooley’s Anemia Foundation, and he is a member of the Committee on Educational Affairs of the American Society of Hematology. Locally, he is the medical director of the Ohio Department of Health Regional Sickle Cell Services Program – Region 1.
MD: University of Texas Southwestern Medical Center, Dallas, TX, 1994.
MS: University of Texas Southwestern Medical Center, Dallas, TX, 2008.
Residency & Chief Residency: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 1998.
Fellowship: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 2001.
Certifications: Pediatrics, 1998; Pediatric Hematology-Oncology, 2002.
McCavit TL, Xuan L, Zhang S, Flores G, Quinn CT. National trends in incidence rates of hospitalization for stroke in children with sickle sell disease. Pediatr Blood Cancer. Epub ahead of print. 2013.
Quinn CT, McKinstry RC, Dowling MM, Ball WS, Kraut MA, Casella JF, Dlamini N, Ichord RN, Jordan LC, Kirkham FJ, Noetzel MJ, Roach ES, Strouse JJ, Kwiatkowski JL, Hirtz D, DeBaun MR. Acute silent cerebral ischemic events in children with sickle cell anemia. JAMA Neurol (formerly Arch Neurol). 2013;70(1):58-65.
Dowling MM, Quinn CT, Plumb P, Rogers ZR, Rollins NK, Koral K, Buchanan GR. Acute silent cerebral ischemia and infarction during acute anemia in children with and without sickle cell disease. Blood. 2012;120(19):3891-7.
Trachtenberg FL, Mednick L, Kwiatkowski JL, Neufeld E, Haines D, Pakbaz Z, Thompson AA, Quinn CT, Grady R, Sobota A, Olivieri N, Horne R, Yamashita R; Thalassemia Clinical Research Network. Beliefs about chelation among thalassemia patients. Health Qual Life Outcomes. 2012;10:148(1-21).
Quinn CT, Dowling MM. Cerebral tissue hemoglobin saturation in children with sickle cell disease. Pediatr Blood Cancer. 2012;59(5):881-887.
Fung EB, Xu Y, Trachtenberg F, Odame I, Kwiatkowski JL, Neufeld EJ, Thompson AA, Boudreaux J, Quinn CT, Vichisnky EP. Inadequate dietary intake in patients with thalassemia. J Acad Nutr Diet. 2012;112(7):980-990.
DeBaun MR, Sarnaik SA, Rodeghier MJ, Minniti CP, Howard TH, Iyer RV, Inusa B, Telfer PT, Kirby-Allen M, Quinn CT, Bernaudin F, Airewele GE, Woods GM, Panepinto JA, Fuh B, Kwiatkowski JK, King AA, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Sabio H, Gonzalez CE, Saccente SL, Kalinyak KA, Strouse JJ, Fixler JM, Hirtz DG, Gordon MO, Miller JP, Ichord, RN, Casella JF. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, gender and relative high systolic blood pressure. Blood. 2012;119(16):3684-90.
Kwiatkowski JL, Kim H-Y, Thompson AA, Quinn CT, Mueller BU, Odame I, Giardina PJ, Vichisnky EP, Boudreaux JM, Porter JB, Coates T, Olivieri NF, Neufeld EJ, Thalassemia Clinical Research Network. Chelation Use and Iron Burden in North American and British Thalassemia Patients: A report from the Thalassemia Longitudinal Cohort. Blood. 2012;119(12):2746-53.
McCavit TL, Lin H, Zhang S, Ahn C, Flores G, Quinn CT. Hospitalization for invasive pneumococcal disease in a national sample of children with sickle cell disease before and after PCV7 licensure. Pediatr Blood Cancer. 2012;58(6):945-9.
Quinn CT, Stuart MJ, Kesler K, Ataga KI, Wang WC, Styles L, Smith-Whitley K, Wun T, Raj A, Hsu L, Krishnan S, Kuypers FA, Setty S, Rhee S, Key NS, Buchanan GR. Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. Br J Haematol. 2011;155(2):263-7.
Measuring RBC Turnover by Stable Isotope Labeling in SCD. Principle Investigator. CCTST T1 Pilot Grant (CTSA). Jun 2012 - May 2013.
Hydroxyurea to prevent CNS complications of sickle cell disease in children. Co-Investigator. National Institutes of Health (NHLBI). Sep 2011 - Jul 2013. # R34HL108756.
A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia. Co-Investigator. National Institutes of Health (NHLBI). Apr 2012 - Mar 2017. #P50HL110790.
Teresa Smolarek, PhD Director, Cytogenetics Laboratory
Director, Cytogenetics Laboratory
PhD: Medical Genetics, Indiana University School of Medicine, 1995.
Certification: American Board of Medical Genetics, Clinical Cytogenetics, 2002; Clinical Molecular Genetics, 2005.
Mehta PA, Harris RE, Davies SM, Kim MO, Mueller R, Lampkin B, Mo J, Myers K, Smolarek TA. Numerical chromosomal changes and risk of development of myelodysplastic syndrome--acute myeloid leukemia in patients with Fanconi anemia. Cancer Genet Cytogenet. 2010 Dec;203(2):180-6. El-Hattab AW, Smolarek TA, Walker ME, Schorry EK, Immken LL, Patel G, Abbott MA, Lanpher BC, Ou Z, Kang SH, Patel A, Scaglia F, Lupski JR, Cheung SW, Stankiewicz P. Redefined genomic architecture in 15q24 directed by patient deletion/duplication breakpoint mapping. Hum Genet. 2009 Oct;126(4):589-602.
Suzuki T, Sakagami T, Rubin BK, Nogee LM, Wood RE, Zimmerman SL, Smolarek T, Dishop MK, Wert SE, Whitsett JA, Grabowski G, Carey BC, Stevens C, van der Loo JC, Trapnell BC. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med. 2008 Nov 24;205(12):2703-10. Bhatla D, Davies SM, Shenoy S, Harris RE, Crockett M, Shoultz L, Smolarek T, Bleesing J, Hansen M, Jodele S, Jordan M, Filipovich AH, Mehta PA. Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome. Bone Marrow Transplant. 2008 Aug;42(3):159-65. Zarate YA, Kogan JM, Schorry EK, Smolarek TA, Hopkin RJ. A new case of de novo 11q duplication in a patient with normal development and intelligence and review of the literature. Am J Med Genet A. 2007 Feb 1;143(3):265-70.
Mehta PA, Ileri T, Harris RE, Williams DA, Mo J, Smolarek T, Auerbach AD, Kelly P, Davies SM. Chemotherapy for myeloid malignancy in children with Fanconi anemia. Pediatr Blood Cancer. 2007 Jun 15;48(7):668-72. D’Armiento J, Imai K, Schiltz J, Kolesnekova N, Sternberg D, Benson K, Pardo A, Selman M, Smolarek T, Vundavalli M, Sonnet J, Szabolcs M and Chada K. Identification of the Benign Mesenchymal Tumor Gene, HMGA2, in Lymphangiomyomatosis (LAM). Cancer Research. 2007;67(5):1902-1909.
Peter H. Tang, PhD Director, Special Chemistry
Director, Special Chemistry
Assistant Professor, UC Department of Pediatrics
In vitro diagnostics; disease monitoring procedures
Mitochondrial dysfunction; metabolic disorders; neurodegenerative diseases; hemoglobin disorders; neurogenesis; and therapeutic drug monitoring
PhD: Analytical Chemistry, University of Cincinnati, Cincinnati, OH, 1990.
MS: Biochemistry, Northeast Louisiana University, Monroe, LA, 1985.
BS: Pharmacy, Taipei Medical College, Taipei, Taiwan, 1978.
Graham DL, Grace CE, Braun AA, Schaefer TL, Skelton MR, Tang PH, Vorhees CV, Williams MT. Effects of developmental stress and lead (Pb) on corticosterone after chronic and acute stress, brain monoamines, and blood Pb levels in rats. Int J Dev Neurosci. 2011 Feb;29(1):45-55.
Miles MV, Putnam PE, Miles L, Tang PH, DeGrauw AJ, Wong BL, Horn PS, Foote HL, Rothenberg ME. Acquired coenzyme Q10 deficiency in children with recurrent food intolerance and allergies. Mitochondrion. 2011 Jan;11(1):127-35.
Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, Saxena V, Tang PH, Miles L, Miles MV, Balistreri WF, Woods SC, Seeley RJ. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology. 2010 Sep;52(3):934-44. Miles MV, Tang PH, Miles L, Steele PE, Moye MJ, Horn PS. Validation and application of an HPLC-EC method for analysis of coenzyme Q10 in blood platelets. Biomed Chromatogr. 2008 Dec;22(12):1403-8. Tang PH. Drug monitoring and toxicology: a simple procedure for the monitoring of felbamate by HPLC-UV detection. J Anal Toxicol. 2008 Jun;32(5):373-8. Herring NR, Schaefer TL, Tang PH, Skelton MR, Lucot JP, Gudelsky GA, Vorhees CV, Williams MT. Comparison of time-dependent effects of (+)-methamphetamine or forced swim on monoamines, corticosterone, glucose, creatine, and creatinine in rats. BMC Neurosci. 2008 May 30;9:49.
Miles MV, Miles L, Tang PH, Horn PS, Steele PE, DeGrauw AJ, Wong BL, Bove KE. Systematic evaluation of muscle coenzyme Q10 content in children with mitochondrial respiratory chain enzyme deficiencies. Mitochondrion. 2008 Mar;8(2):170-80. Miles MV, Patterson BJ, Chalfonte-Evans ML, Horn PS, Hickey FJ, Schapiro MB, Steele PE, Tang PH, Hotze SL. Coenzyme Q10 (ubiquinol-10) supplementation improves oxidative imbalance in children with trisomy 21. Pediatr Neurol. 2007 Dec;37(6):398-403. Tang PH, Miles MV, Steele P, Davidson BS, Geraghty SR, Morrow AL. Determination of coenzyme Q10 in human breast milk by high-performance liquid chromatography. Biomed Chromatogr. 2006 Dec;20(12):1336-43.Tang PH. Determination of coenzyme Q10 in over-the-counter dietary supplements by high-performance liquid chromatography with coulometric detection. J AOAC Int. 2006 Jan-Feb;89(1):35-9.
Jeffrey A. Towbin, MD, FAAP, FACC, FAHA Executive Co-Director, Heart Institute; Chief, Pediatric Cardiology
Executive Co-Director, Heart Institute; Chief, Pediatric Cardiology
Director, Heart Institute Diagnostic Laboratory
BS: Biology, University of Cincinnati, 1974.MS: Cell Biology, University of Cincinnati, 1977.MD: University of Cincinnati, 1982.
Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, 1985.
Fellowship: Pediatric Cardiology, Baylor College of Medicine, Texas Children's Hospital, 1989.
McBride KL, Zender GA, Fitzgerald-Butt SM, Seagraves NJ, Fernbach SD, Zapata G, Lewin M, Towbin JA, Belmont JW. Association of common variants in ERBB4 with congenital left ventricular outflow tract obstruction defects. Birth Defects Res A Clin Mol Teratol. 2011 Mar;91(3):162-8.
Fakhro KA, Choi M, Ware SM, Belmont JW, Towbin JA, Lifton RP, Khokha MK, Brueckner M. Rare copy number variations in congenital heart disease patients identify unique genes in left-right patterning. Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):2915-20.
Goldenberg I, Horr S, Moss AJ, Lopes CM, Barsheshet A, McNitt S, Zareba W, Andrews ML, Robinson JL, Locati EH, Ackerman MJ, Benhorin J, Kaufman ES, Napolitano C, Platonov PG, Priori SG, Qi M, Schwartz PJ, Shimizu W, Towbin JA, Vincent GM, Wilde AA, Zhang L. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol. 2010 Dec 28;57(1):51-9.
Towbin JA, Ware SM, Jefferies JL. Heart transplants in pediatric patients: viral infection as a loss predictor. Future Cardiol. 2010 Nov;6(6):735-41.
Foerster SR, Canter CE, Cinar A, Sleeper LA, Webber SA, Pahl E, Kantor PF, Alvarez JA, Colan SD, Jefferies JL, Lamour JM, Margossian R, Messere JE, Rusconi PG, Shaddy RE, Towbin JA, Wilkinson JD, Lipshultz SE. Ventricular remodeling and survival are more favorable for myocarditis than for idiopathic dilated cardiomyopathy in childhood: an outcomes study from the Pediatric Cardiomyopathy Registry. Circ Heart Fail. 2010 Nov 1;3(6):689-97.
Purevjav E, Varela J, Morgado M, Kearney DL, Li H, Taylor MD, Arimura T, Moncman CL, McKenna W, Murphy RT, Labeit S, Vatta M, Bowles NE, Kimura A, Boriek AM, Towbin JA. Nebulette mutations are associated with dilated cardiomyopathy and endocardial fibroelastosis. J Am Coll Cardiol. 2010 Oct 26;56(18):1493-502. Towbin JA. Left ventricular noncompaction: a new form of heart failure. Heart Fail Clin. 2010 Oct;6(4):453-69 Towbin JA. Preface: Heart failure in children. Heart Fail Clin. 2010 Oct;6(4):xvii-iii.
Wilkinson JD, Landy DC, Colan SD, Towbin JA, Sleeper LA, Orav EJ, Cox GF, Canter CE, Hsu DT, Webber SA, Lipshultz SE. The pediatric cardiomyopathy registry and heart failure: key results from the first 15 years. Heart Fail Clin. 2010 Oct;6(4):401-13 Towbin JA. Hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. 2009 Jul;32 Suppl 2:S23-31.
David P. Witte, MD Director, Pathology
Director, Mass Spectrometry Laboratory
Professor, UC Department of Pathology & Laboratory Medicine
Molecular pathology; pediatric renal pathology
MD: University of Cincinnati, Cincinnati, Ohio, 1979.
Residency: Pediatrics, Washington University, St. Louis, Mo., 1979-1980; Pathology, Washington University, St. Louis, Mo., 1980-1984.
Fellowship: Pathology, Children's Hospital Medical Center, Cincinnati, Ohio, 1984-1986; Research Scholar, Pathology, Children's Hospital Medical Center, Cincinnati, Ohio, 1986-1989.
Certification: Anatomic Pathology, American Board of Pathology, 1985; Pediatric Pathology, American Board of Pathology, 1991.
Kejian Zhang, MD, MBA Director, Molecular Genetics Laboratory
Director, Molecular Genetics Laboratory
Molecular genetics diagnosis of inherited immunodeficiency disorders and other genetic conditions
Molecular defects and molecular diagnosis of primary immunodeficiency diseases; Genetic aspects of predictive personalized medicine (pharmacogenetics)
MD: Tianjin Medical University, Tianjin, China, 1993
MBA: University of Cincinnati, College of Business Administration, 2001
Residency: Gong'an Hospital, Tianjin, China, 1993-1995
Fellowship: Clinical Molecular Genetics Fellow, Division of Human Genetics, Cincinnati Children's Hospital, 2002-2004
Zhang K, Jordan MB, Klein P, Villanueva J, Risma K, Filipovic AH. .Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial hemophagocytic lymphohistiocytosis. Blood. 2011 August 31.
Filipovich AH, Zhang K, Snow AL, Marsh RA. X-linked lymphoproliferative syndromes: brothers or distant cousins? Blood. 2010 Nov 4;116(18):3398-408.
Marsh RA, Madden L, Kitchen BJ, Mody R, McClimon B, Jordan MB, Bleesing JJ, Zhang K, Filipovich AH. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood. 2010 Aug 19;116(7):1079-82.
Marsh RA, Satake N, Biroschak J, Jacobs T, Johnson J, Jordan MB, Bleesing JJ, Filipovich AH, Zhang K. STX11 mutations and clinical phenotypes of familial hemophagocytic lymphohistiocytosis in North America. Pediatr Blood Cancer. 2010 Jul 15;55(1):134-40. Pestian J, Spencer M, Matykiewicz P, Zhang K, Vinks AA, Glauser T. Personalizing Drug Selection Using Advanced Clinical Decision Support. Biomed Inform Insights. 2009 Jun 23;2:19-29. Prows CA, Nick TG, Saldaña SN, Pathak S, Liu C, Zhang K, Daniels ZS, Vinks AA, Glauser TA. Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients. J Child Adolesc Psychopharmacol. 2009 Aug;19(4):385-94. Marsh RA, Villanueva J, Kim MO, Zhang K, Marmer D, Risma KA, Jordan MB, Bleesing JJ, Filipovich AH. Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T-cell populations. Clin Immunol. 2009 Jul;132(1):116-23. Marsh RA, Villanueva J, Zhang K, Snow AL, Su HC, Madden L, Mody R, Kitchen B, Marmer D, Jordan MB, Risma KA, Filipovich AH, Bleesing JJ. A rapid flow cytometric screening test for X-linked lymphoproliferative disease due to XIAP deficiency. Cytometry B Clin Cytom. 2009 Sep;76(5):334-44. Prausa SE, Fukuda T, Maseck D, Curtsinger KL, Liu C, Zhang K, Nick TG, Sherbotie JR, Ellis EN, Goebel J, Vinks AA. UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009 May;85(5):495-500. Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, Binstadt BA, Filipovich A, Grom AA. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 2008 Sep;58(9):2892-6.
Macrophage Activation Syndrome Biomarkers in Systemic Juvenile Idiopathic Arthritis. Co-investigator. National Institute of Arthritis, Musculoskeletal and Skin Diseases. Aug 2007 - Dec 2012.
MUNC13-4 gene Polymorphisms in Macrophage Activation syndrome and Systemic Juvenile Idiopathic Arthritis. Co-Investigator. National Institute of Health. Sept 2011 - Aug 2016.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2014 Cincinnati Children's Hospital Medical Center